• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials
patient education

Endari: A Treatment Option for Sickle Cell Disease

key information

source: Sickle Options

year: N/A


Endari is an amino acid, approved by Food and Drug Administration (FDA) to treat sickle cell disease. It is available in powder form to be taken orally. 

The exact mechanism of action of Endari is not fully understood but it increases the amount of free glutamine in the blood.  Glutamine is used to make anti-oxidant molecules which reduce the oxidative stress in sickle red blood cells resulting in increased flexibility of red blood cells while they travel through the body. 

Safety profile of Endari is not available for children less than 5 years of age and risk of taking Endari in pregnancy is not known yet.

read more

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.